Roche Raises IO Credentials On Tecentriq Lung Cancer Data

With positive overall survival data from the Phase III OAK trial of Tecentriq in non-small cell lung cancer, Roche enters the top flight of immuno-oncology companies alongside Merck and Bristol-Myers Squibb.